Literature DB >> 9858251

Factor V Arg306-->Thr (factor V Cambridge) and factor V Arg306-->Gly mutations in venous thrombotic disease.

R F Franco1, F H Maffei, D Lourenço, V Morelli, I A Thomazini, C E Piccinato, M H Tavella, M A Zago.   

Abstract

We investigated the prevalence of two reported mutations of the factor V gene (factor V Arg306-->Thr, or factor V Cambridge, and factor V Arg306-->Gly) in 104 relatively young patients with verified venous thrombosis and in 208 age-, sex- and race-matched controls, in order to establish whether the two mutations are associated with increased predisposition for venous thrombosis. PCR amplification followed by BstNI and MspI digestion was employed to determine the genotypes, and each mutation was confirmed by DNA sequencing. Among the controls, one individual was found to be heterozygous for the factor V Arg306-->Thr mutation and one heterozygous for the factor VArg306-->Gly mutation; none of the patients carried either mutation. Our findings do not support factor V Cambridge and factor V Arg306-->Gly as risk factors for venous thrombosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9858251     DOI: 10.1046/j.1365-2141.1998.01051.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

1.  Cleavage at both Arg306 and Arg506 is required and sufficient for timely and efficient inactivation of factor Va by activated protein C.

Authors:  Melissa A Barhoover; Michael Kalafatis
Journal:  Blood Coagul Fibrinolysis       Date:  2011-06       Impact factor: 1.276

2.  Polymorphisms at activated protein C cleavage sites of factor V: Are they important in the absence of factor V Leiden?

Authors:  Ehsan Kheradmand; Shaghayegh Haghjooy-Javanmard; Leila Dehghani; Mohammad Saadatnia
Journal:  Iran J Neurol       Date:  2017-01-05

3.  American College of Medical Genetics consensus statement on factor V Leiden mutation testing.

Authors:  W W Grody; J H Griffin; A K Taylor; B R Korf; J A Heit
Journal:  Genet Med       Date:  2001 Mar-Apr       Impact factor: 8.822

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.